Alkem Laboratories Peer Comparison

Snapshot Summary

Alkem Laboratories Ltd. stands out in the pharmaceuticals sector with impressive profitability metrics and solid growth, making it a strong competitor among its peers. Despite a moderate valuation, it remains a compelling choice for investors seeking stability and growth.

• Alkem has a strong ROE of 19.93% and healthy profit margins, indicating solid profitability.
• Its PEG ratio of 0.17 suggests it is undervalued relative to its growth, making it an attractive investment.
• Compared to peers, Alkem's low debt-equity ratio (0.0889) suggests a conservative capital structure.

• Mankind Pharma Ltd.: Highest revenue growth (YoY at 18.12%) and strong profitability with an ROE of 23.15%.
• Dr. Reddy's Laboratories Ltd.: Best overall profitability with the highest ROA (16.08%) and low PE ratio (15.50), indicating strong value.
• Cipla Ltd.: Consistent growth with a revenue YoY of 13.28% and attractive PEG ratio of 0.35.

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
ALKEM	₹5,299.25	₹63,360.48Cr	30.32	21.56%	0.09
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Alkem Laboratories Peer Comparison

Snapshot Summary